Masatomo Taniguchi
Overview
Explore the profile of Masatomo Taniguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
1697
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishimoto M, Hasegawa T, Murashima M, Noma H, Nishiwaki H, Yamada S, et al.
Clin J Am Soc Nephrol
. 2025 Mar;
PMID: 40085178
Background: It is necessary to update the evidence of each phosphate-lowering agent on dialysis patients. Methods: From the CENTRAL, MEDLINE, EMBASE, and ClinicalTrial.gov databases, randomized controlled trials (RCTs) using oral...
2.
Goto S, Hamano T, Taniguchi M, Abe M, Nitta K, Nishi S, et al.
Sci Rep
. 2025 Mar;
15(1):8089.
PMID: 40057535
In hemodialysis patients, it remains unclear whether patient characteristics influence the clinical impacts of changes in serum mineral metabolism parameters on mortality. In this 9-year cohort study, we investigated the...
3.
Goto S, Hamano T, Fujii H, Taniguchi M, Abe M, Nitta K, et al.
Clin Kidney J
. 2024 Oct;
17(10):sfae263.
PMID: 39385948
Background: In cohort studies of hyperphosphatemic hemodialysis patients, reduced serum phosphate levels have been linked to a lower mortality risk. To investigate whether this benefit is influenced by patient characteristics,...
4.
Kohara C, Yamada S, Tanaka S, Hiyamuta H, Kitamura H, Arase H, et al.
J Am Heart Assoc
. 2024 Aug;
13(15):e033853.
PMID: 39101503
Background: Lower extremity peripheral arterial disease is a potentially lethal cardiovascular complication in patients undergoing hemodialysis. Anemia is a risk factor for cardiovascular disease among the hemodialysis population. However, whether...
5.
Arase H, Yamada S, Taniguchi M, Ooboshi H, Tsuruya K, Kitazono T, et al.
Clin Kidney J
. 2024 Jun;
17(6):sfae154.
PMID: 38919276
Background: Disturbances in the cardiovascular system, bone and skeletal muscle are independent risk factors for death among patients receiving haemodialysis (HD). However, the combined impact of disorders of these three...
6.
Wakamatsu T, Yamamoto S, Matsuo K, Taniguchi M, Hamano T, Fukagawa M, et al.
J Bone Miner Metab
. 2024 Mar;
42(3):316-325.
PMID: 38536478
Introduction: This study aimed to assess the effectiveness of calcimimetics in reducing the risk of fractures in dialysis patients with secondary hyperparathyroidism (SHPT). Material And Methods: A comprehensive literature search...
7.
Haruyama N, Nakayama M, Yamada S, Tanaka S, Hiyamuta H, Taniguchi M, et al.
J Bone Miner Metab
. 2024 Mar;
42(2):253-263.
PMID: 38509305
Introduction: In patients undergoing dialysis, major bone fracture is associated with a high risk of mortality, including death of cardiovascular (CV) origin. In the present study, we aimed to determine...
8.
Nakai K, Kono K, Yamada S, Taniguchi M, Hamano T, Fukagawa M
Ther Apher Dial
. 2024 Mar;
28(4):557-571.
PMID: 38499495
Introduction: Several calcimimetics, other than cinacalcet, are commercially available; however, their effects on calcium and phosphate levels have not yet been fully studied. We conducted a systematic review and meta-analysis...
9.
Yamada S, Arase H, Taniguchi M, Kitazono T, Nakano T
Ther Apher Dial
. 2023 Nov;
28(2):206-217.
PMID: 37945327
Introduction: Malnutrition-inflammation complex syndrome (MICS) is highly prevalent in patients undergoing hemodialysis. We determined the prognostic value of the Simple MICS score, calculated using a combination of age, body mass...
10.
Goto S, Hamano T, Fujii H, Taniguchi M, Abe M, Nitta K, et al.
Nephrol Dial Transplant
. 2023 Oct;
39(4):637-647.
PMID: 37777840
Background: Calcimimetics are widely used in hemodialysis patients and influence serum calcium levels. Although the Kidney Disease: Improving Global Outcomes guidelines argued that low calcium levels induced by calcimimetics may...